Health on MSN3d
What's the Difference Between Asthma and Chronic Obstructive Pulmonary Disease (COPD)?
Medically reviewed by Sanja Jelic, MD Asthma and chronic obstructive pulmonary disease (COPD) are chronic respiratory (lung) ...
From cancer vaccines to COPD treatments, these 10 companies are developing innovative medicines
Eli Lilly, Adaptimmune, Aurion Biotech, and ImmunityBio had breakthrough medicines and therapies debut in the past year.
Healio19h
‘The earlier, the better’: Use spirometry to detect COPD during lung cancer screenings
Due to the destructive nature of COPD on patients’ lungs and well-being, timely diagnosis is key, and integrating spirometry ...
Medindia1d
Nasal Proteins Provide Vital Clues for Early COPD Diagnosis
Elevated IL-26 levels in the nose of smokers with and without COPD may provide a simple method for early detection and ...
Regeneron (NASDAQ:REGN) and Sanofi Get Japan Green Light for Smokers’ Lung Disease Treatment
Biotech company Regeneron (REGN) and French pharmaceutical giant Sanofi (SNY) today announced that Japan has granted ...
Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD)
Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in adults with elevated eosinophils ...
Medindia6d
Inhaled Corticosteroids for Lung Disease: Relief Today, Risk Tomorrow
Long-term inhaled corticosteroid (ICS) use for chronic obstructive pulmonary disease/ COPD (lung disease) may increase the ...
WebMD9d
Everyday Tips for Living With COPD
Chronic obstructive pulmonary disease (COPD) is a challenge ... and more coughing -- so you can call your doctor right away. Treatments for COPD can include lifestyle changes, oral and inhaled ...
Adverse outcomes increased with long-term inhaled corticosteroids in COPD
For patients with chronic obstructive pulmonary disorder (COPD), long-term inhaled corticosteroid (ICS) treatment is ...
Pharmabiz3d
Sanofi & Regeneron’s Dupixent receives Japanese marketing approval to treat patients with COPD
Sanofi & Regeneron’s Dupixent receives Japanese marketing approval to treat patients with COPD: Paris Saturday, March 29, 2025, 09:00 Hrs [IST] The Ministry of Health, Labour an ...
Yahoo Finance4d
Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD)
Dupixent for the treatment of COPD has been approved in more than 45 countries worldwide, including the 27 member countries of the European Union (EU). COPD is a chronic respiratory disease that ...